Table 5. Sensitivity, Specificity, Positive and Negative Predictive Values and Receiver Operating Curve Model of the SARC-F, SARC-CalF, MSRA-5 and MSRA-7 questionnaires against six sets of international diagnostic criteria of sarcopenia in the whole study population.
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | AUC | |
|---|---|---|---|---|---|
| FNIH | |||||
| SARC-F | 90.0 (55.5–99.8) | 91.1 (83.2–96.1) | 52.9 (36.0–69.2) | 98.8 (92.7–99.8) | 0.882 (0.726–1.000)b,c,d |
| SARC-CalF | 20.0 (2.5–55.6) | 80.0 (70.3–87.7) | 10.0 (2.9–29.1) | 90.0 (86.7–92.6) | 0.711 (0.556–0.865)a |
| MSRA-5 | 90.0 (55.5–99.8) | 47.8 (37.1–58.6) | 16.1 (12.6–20.3) | 97.7 (86.8–99.6) | 0.669 (0.539–0.799)a |
| MSRA-7 | 90.0 (55.5–99.8) | 30.0 (20.8–40.6) | 12.5 (10.0–15.5) | 96.4 (80.4–99.4) | 0.619 (0.463–0.775)a |
| AWGS | |||||
| SARC-F | 37.5 (15.2–64.6) | 86.9 (77.8–93.3) | 35.3 (14.2–61.7) | 88.0 (79.0–94.1) | 0.655 (0.496–0.814)b |
| SARC-CalF | 62.5 (35.4–84.8) | 88.1 (79.2–94.1) | 50.0 (27.2–72.8) | 92.5 (84.4–97.2) | 0.786 (0.636–0.936)a |
| MSRA-5 | 81.3 (54.4–96.0) | 48.8 (37.7–60.0) | 23.2 (13.0–36.4) | 93.2 (81.3–98.6) | 0.728 (0.582–0.873) |
| MSRA-7 | 87.5 (61.7–98.4) | 31.0 (21.3–42.0) | 19.4 (11.1–30.5) | 92.9 (76.5–99.1) | 0.668 (0.519–0.816) |
| EWGSOP1 | |||||
| SARC-F | 35.0 (15.4–59.2) | 87.5 (78.2–93.8) | 41.2 (18.4–67.1) | 84.3 (79.0–94.1) | 0.658 (0.513–0.802)b |
| SARC-CalF | 60.0 (36.1–80.9) | 90.0 (81.2–95.6) | 60.0 (36.1–80.9) | 90.0 (81.2–95.6) | 0.816 (0.691–0.940)a,d |
| MSRA-5 | 70.0 (45.7–88.1) | 47.5 (36.2–59.0) | 25.0 (14.4–38.4) | 86.4 (72.6–94.8) | 0.653 (0.510–0.796) |
| MSRA-7 | 80.0 (56.3–94.3) | 30.0 (20.3–41.3) | 22.2 (13.3–33.6) | 85.7 (67.3–96.0) | 0.608 (0.467–0.750)b |
| EWGSOP2 | |||||
| SARC-F | 41.2 (18.4–67.1) | 88.0 (79.0–94.1) | 41.2 (18.4–67.1) | 88.0 (79.0–94.1) | 0.719 (0.579–0.859) |
| SARC-CalF | 64.7 (38.3–85.8) | 89.2 (80.4–94.9) | 55.0 (31.5–76.9) | 92.5 (84.4–97.2) | 0.792 (0.648–0.936)d |
| MSRA-5 | 64.7 (38.3–85.8) | 45.8 (34.8–57.1) | 19.6 (10.2–32.4) | 86.4 (72.6–94.8) | 0.618 (0.460–0.776) |
| MSRA-7 | 76.5 (50.1–93.2) | 28.9 (19.5–39.9) | 18.1 (10.0–28.9) | 85.7 (67.3–96.0) | 0.588 (0.431–0.746)b |
| IWGS | |||||
| SARC-F | 50.0 (21.1–78.9) | 87.5 (78.7–93.6) | 35.3 (14.2–61.7) | 92.8 (84.9–97.3) | 0.732 (0.555–0.908) |
| SARC-CalF | 66.7 (34.9–90.1) | 86.4 (77.4–92.8) | 40.0 (19.1–63.9) | 95.0 (87.7–98.6) | 0.846 (0.704–0.988) |
| MSRA-5 | 83.3 (51.6–97.9) | 47.7 (37.0–58.6) | 17.9 (8.9–30.4) | 95.5 (84.5–99.4) | 0.767 (0.614–0.920) |
| MSRA-7 | 91.7 (61.5–99.8) | 30.7 (21.3–41.4) | 15.3 (7.9–25.7) | 96.4 (81.7–99.9) | 0.711 (0.556–0.866) |
| SCWD | |||||
| SARC-F | 50.0 (21.1–78.9) | 87.5 (78.7–93.6) | 35.3 (14.2–61.7) | 92.8 (84.9–97.3) | 0.719 (0.543–0.895)b |
| SARC-Cal-F | 75.0 (42.8–94.5) | 87.5 (78.7–93.6) | 45.0 (23.1–68.5) | 96.3 (89.4–99.2) | 0.874 (0.735–1.000)a |
| MSRA-5 | 83.3 (51.6–97.9) | 47.7 (37.0–58.6) | 17.9 (8.9–30.4) | 95.5 (84.5–99.4) | 0.782 (0.642–0.921) |
| MSRA-7 | 91.7 (61.5–99.8) | 30.7 (21.3–41.4) | 15.3 (7.9–25.7) | 96.4 (81.7–99.9) | 0.711 (0.556–0.866) |
Data are presented with the 95% CI in parenthesis
a–Significantly different with SARC-F (p<0.05)
b–Significantly different with SARC-Cal-F (p<0.05)
c–Significantly different with MSRA-5 (p<0.05)
d–Significantly different with MSRA-7 (p<0.05); Abbreviations: PPV, Positive Predictive Values; NPV, Negative Predictive Values; AUC area under the curve; MSRA, Mini Sarcopenia Risk Assessment; EWGSOP1, the European Working Group on Sarcopenia in Older People; EWGSOP2, extended group for the European Working Group on Sarcopenia in Older People; FNIH, the Foundation for the National Institutes of Health; AWGS, Asian Working Group on Sarcopenia; IWGS, the International Working Group on Sarcopenia; SCWD, the Society on Sarcopenia, Cachexia and Wasting Disorders